Haploidentical donor transplant is associated with secondary poor graft function after allogeneic stem cell transplantation: A single-center retrospective study

被引:14
作者
Lv, Wei-Ran [1 ]
Zhou, Ya [1 ]
Xu, Jun [1 ]
Fan, Zhi-Ping [1 ]
Huang, Fen [1 ]
Xu, Na [1 ]
Xuan, Li [1 ]
Shi, Peng-Cheng [1 ]
Liu, Hui [1 ]
Wang, Zhi-Xiang [1 ]
Sun, Jing [1 ]
Liu, Qi-Fa [1 ]
机构
[1] Southern Med Univ, Nanfang Hosp, Dept Hematol, Guangzhou 510515, Guangdong, Peoples R China
来源
CANCER MEDICINE | 2021年 / 10卷 / 23期
基金
中国国家自然科学基金;
关键词
haploidentical donor transplant; hazard elements; hematopoietic stem cell transplantation; secondary poor graft function; VERSUS-HOST-DISEASE; HUMAN CYTOMEGALOVIRUS; RISK-FACTORS; INFECTION; FAILURE; BLOOD; ELTROMBOPAG; SUPPRESSION; ENGRAFTMENT; RECOVERY;
D O I
10.1002/cam4.4353
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Secondary poor graft function (sPGF) is a serious complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT) related to poor outcome. We aimed to retrospectively evaluate the morbidity and hazard elements of sPGF after allo-HSCT. Methods Eight hundred and sixty-three patients who achieved initial engraftment of both neutrophils and platelets were retrospectively reviewed in this study. Results Fifty-two patients developed sPGF within 180 days post-transplants, with the median onset time was 62 days (range, 34-121 days) post-transplants. The overall cumulative incidence of sPGF within 180 days post-transplantation was 6.0%, with 3.4%, 3.4%, and 10.1%, respectively, in matched sibling donor (MSD), matched unrelated donor (MUD), and haploidentical donor (HID) transplant (p < 0.0001). Multivariable analysis showed that HID (HID vs. MSD: hazard ratio [HR] 2.525, p = 0.004; HID vs. MUD: [HR] 3.531, p = 0.017), acute graft versus host disease (aGVHD) within +30 days ([HR] 2.323, p = 0.003), and cytomegalovirus (CMV) reactivation ([HR] 8.915, p < 0.0001) within +30 days post-transplants were hazard elements of sPGF. The patients with sPGF had poorer survival than good graft function (51.7 +/- 8.1% vs. 62.9 +/- 1.9%, p < 0.0001). Our results also showed that only CMV reactivation was the hazard element for the development of PGF in HID transplant ([HR] 12.521 p < 0.0001). Conclusion HID transplant is also an independent hazard element of sPGF except for aGVHD and CMV reactivation.
引用
收藏
页码:8497 / 8506
页数:10
相关论文
共 34 条
  • [1] Al Malki MM, 2017, BLOOD, V130
  • [2] Cotransplantation of ex vivo-expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation
    Ball, Lynne M.
    Bernardo, Maria Ester
    Roelofs, Helene
    Lankester, Arjan
    Cometa, Angela
    Egeler, R. Maarten
    Locatelli, Franco
    Fibbe, Willem E.
    [J]. BLOOD, 2007, 110 (07) : 2764 - 2767
  • [3] Cotransplantation of Mesenchymal Stem Cells Might Prevent Death from Graft-versus-Host Disease (GVHD) without Abrogating Graft-versus-Tumor Effects after HLA-Mismatched Allogeneic Transplantation following Nonmyeloablative Conditioning
    Baron, Frederic
    Lechanteur, Chantal
    Willems, Evelyne
    Bruck, France
    Baudoux, Etienne
    Seidel, Laurence
    Vanbellinghen, Jean-Francois
    Hafraoui, Kaoutar
    Lejeune, Marie
    Gothot, Andre
    Fillet, Georges
    Beguin, Yves
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (06) : 838 - 847
  • [4] Granulocyte colony-stimulating factor for poor graft function after allogeneic stem cell transplantation: 3 days of G-CSF identifies long-term responders
    Bittencourt, H
    Rocha, V
    Filion, A
    Ionescu, I
    Herr, AL
    Garnier, F
    Ades, L
    Esperou, H
    Devergie, A
    Ribaud, P
    Socie, G
    Gluckman, E
    [J]. BONE MARROW TRANSPLANTATION, 2005, 36 (05) : 431 - 435
  • [5] BOLGER GB, 1986, BONE MARROW TRANSPL, V1, P21
  • [6] Donor-Specific Anti-HLA Antibodies in Haploidentical Stem Cell Transplantation with Post-Transplantation Cyclophosphamide: Risk of Graft Failure, Poor Graft Function, and Impact on Outcomes
    Bramanti, Stefania
    Calafiore, Valeria
    Longhi, Elena
    Mariotti, Jacopo
    Crespiatico, Loretta
    Sarina, Barbara
    De Philippis, Chiara
    Nocco, Angela
    Santoro, Armando
    Castagna, Luca
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (07) : 1395 - 1406
  • [7] Platelet Engraftment in Patients with Hematologic Malignancies following Unmanipulated Haploidentical Blood and Marrow Transplantation: Effects of CD34+ Cell Dose and Disease Status
    Chang, Ying-Jun
    Xu, Lan-Ping
    Liu, Dai-Hong
    Liu, Kai-Yan
    Han, Wei
    Chen, Yu-Hong
    Yu-Wang
    Chen, Huan
    Wang, Jing-Zhi
    Zhang, Xiao-Hui
    Zhao, Xiang-Yu
    Huang, Xiao-Jun
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (05) : 632 - 638
  • [8] Donor-specific anti-HLAAbs and graft failure in matched unrelated donor hematopoietic stem cell transplantation
    Ciurea, Stefan O.
    Thall, Peter F.
    Wang, Xuemei
    Wang, Sa A.
    Hu, Ying
    Cano, Pedro
    Aung, Fleur
    Rondon, Gabriela
    Molldrem, Jeffrey J.
    Korbling, Martin
    Shpall, Elizabeth J.
    de Lima, Marcos
    Champlin, Richard E.
    Fernandez-Vina, Marcelo
    [J]. BLOOD, 2011, 118 (22) : 5957 - 5964
  • [9] Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft-versus-host disease, donor type, cytomegalovirus infections and cell dose
    Dominietto, A
    Raiola, AM
    van Lint, MT
    Lamparelli, T
    Gualandi, F
    Berisso, G
    Bregante, S
    Frassoni, F
    Casarino, L
    Verdiani, S
    Bacigalupo, A
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2001, 112 (01) : 219 - 227
  • [10] Eltrombopag after allogeneic haematopoietic cell transplantation in a case of poor graft function and systematic review of the literature
    Dyba, J.
    Tinmouth, A.
    Bredeson, C.
    Matthews, J.
    Allan, D. S.
    [J]. TRANSFUSION MEDICINE, 2016, 26 (03) : 202 - 207